Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

This trial is testing whether low-dose continuous capecitabine (an oral chemotherapy) taken after completing standard treatment can reduce the risk of head and neck squamous cell cancer coming back in patients who had locally advanced disease. **You may be eligible if...** - You have completed treatment (surgery plus radiation, or chemoradiation) for stage III or IV squamous cell cancer of the mouth, throat, larynx, or hypopharynx - You are within 4–8 weeks of finishing your last radiation dose - There is no sign of remaining or spread cancer - Your blood counts and organ function are adequate - Your performance status is ECOG 0 or 1 **You may NOT be eligible if...** - Your cancer has come back or spread at the time of enrollment - You have had a prior head and neck cancer - You have significant heart, kidney, or liver disease - You are pregnant or breastfeeding - You have a known allergy to capecitabine or fluorouracil - You cannot swallow tablets Talk to your doctor to see if this trial is right for you.